ValiRx Share News (VAL)
VAL Share
VAL Share
VAL Share
VAL Share
VAL
VAL Share
VAL Level 2
VAL Live
VAL Broker
VAL Directors
VAL Financial
VAL
VAL Short
VAL
Last checked at -
Mon, 06th Jul 2020 18:19
ValiRx PLC - London-based clinical stage biotechnology company - Lays out strategy to build on portfolio of drug candidates in the oncology and women's health space. "The company plans to apply both intellectual and financial resources to each project and enable acceleration through pre-clinical development," ValiRx said.
Current stock price: 8.12 pence
Year-to-date change: down 46%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments. The studies on treatment VAL401 were carried out by Valiseek, Valirx's joint venture company with Tangent Reprofiling, and demonstrate
Read more
Last checked at